Recent News

• 02.12.2026 - TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
• 02.02.2026 - TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
• 12.15.2025 - TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
• 12.11.2025 - TuHURA Biosciences Provides Corporate Update Following Recent Financing
• 12.09.2025 - TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering
• 12.08.2025 - TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
• 11.14.2025 - TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Recent Filings

• 01.30.2026 - 8-K Current report
• 01.08.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.08.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.10.2025 - EX-99.1 EX-99.1
• 12.10.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.10.2025 - 8-K Current report
• 12.05.2025 - 8-K Current report
• 11.25.2025 - 8-K Current report